Upfront Maintenance Poly(Adenosine Diphosphate Ribose) Polymerase Inhibitors in Ovarian Cancer: A Ray of Hope or Just a Mirage!

Abstract

Poly(adenosine diphosphate ribose) polymerase inhibitors (PARPis), when used in patients harboring tumor with homologous recombination deficiency, with or without BRCA mutation, have shown favorable outcomes in relapsed, advanced metastatic breast and ovarian cancers. Olaparib, niraparib, and rucaparib have been approved as maintenance therapy in platinum-sensitive, relapsed, high-grade epithelial ovarian cancer (EOC) responsive to platinum doublet. Olaparib and rucaparib as monotherapy are also indicated in patients who have progressed on three or more lines of chemotherapy, irrespective of platinum sensitivity, in germline or somatic BRCA 1/2-mutated, PARPi-naive patients. Recently, four large multicentric, international Phase III randomized clinical trials have reported outcomes of PARPi in first-line advanced EOC as maintenance therapy either alone or in combination with bevacizumab. Previously bevacizumab, pazopanib, nindetanib, or maintenance chemotherapy in first-line setting has resulted in modest improvements in progression free survival, albeit with significant toxicities and poor cost-effectiveness. We offer in this review to dissect the data pertaining to randomized clinical trials of PARPi use as maintenance therapy in upfront EOCs and ruminate about its role in the contemporary management of ovarian cancers.

Keywords

Epithelial ovarian cancer - maintenance therapy - poly (adenosine diphosphate ribose) polymerase inhibitors

• References

• 1 Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108
• 2 Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N. et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010; 363: 943-53
• 3 Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA. et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335: 1950-5
• 4 Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S. et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43
• 5 Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S. et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): A randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2014; 15: 396-405
• 6 Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E. et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): A randomised, controlled, open-label trial. Lancet Oncol 2013; 14: 1020-6
• 7 Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-83
• 8 Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G. et al. Aphase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-96
• 9 Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E. et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial. Lancet Oncol 2015; 16: 928-36
• 10 du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M. et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 2014; 32: 3374-82
• 11 Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M. et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018; 379: 2495-505
• 12 Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M. et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 2019; 381: 2403-15
• 13 González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2019; 381: 2391-402
• 14 Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martin A, Sevelda P. et al. Phase III PAOLA-1/ENGOT-ov25: maintenance olaparib with bevacizumab in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy and bevacizumab as standard of care. Ann Oncol 2017; 30(Suppl 5): v851-934
• 15 Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib Plus Bevacizumab as Maintenance Therapy in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with Platinum-based Chemotherapy Plus Bevacizumab. https://oncologypro.esmo.org/Meeting-Resources/ESMO-2019-Congress/Phase-III-PAOLA-1-ENGOT-ov25-trial-Olaparib-plus-bevacizumab-bev-as-maintenance-therapy-in-patients-pts-with-newly-diagnosed-advanced-ovarian-cancer-OC-treated-with-platinum-based-chemotherapy-PCh-plus-bev Available from: [Last accessed on 2020 Jan 05]
• 16 Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M. et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009; 361: 123-34
• 17 O'Connor MJ. Targeting the DNA damage response in cancer. Mol Cell 2015; 60: 547-60
• 18 McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res 2006; 66: 8109-15
• 19 Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci U S A 2008; 105: 17079-84
• 20 Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J. et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015; 33: 244-50
• 21 Matulonis UA, Penson RT, Domchek SM, Kaufman B, Shapira-Frommer R, Audeh MW. et al. Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: A multistudy analysis of response rates and safety. Ann Oncol 2016; 27: 1013-9
• 22 Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017; 18: 1274-84
• 23 Hinde S, Epstein D, Cook A, Embleton A, Perren T, Sculpher M. et al. The cost-effectiveness of bevacizumab in advanced ovarian cancer using evidence from the ICON7 trial. Value Health 2016; 19: 431-9
• 24 du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N. et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2016; 17: 78-89
• 25 Norquist BS, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner SI. et al. Mutations in homologous recombination genes and response to treatment in GOG 218: An NRG oncology study. Gynecol Oncol 2016; 141: 2
• 26 Harter P, Johnson T, Berton-Rigaud D, Park SY, Friedlander M, Del Campo JM. et al. BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study. Gynecol Oncol 2016; 140: 443-9
• 27 Rohit K, Gupta S, Rajappa SJ, Advani SH, Agarwal A, Aggarwal S. et al. A non-interventional, multicenter study to assess prevalence of BRCA1 and BRCA2 mutation among ovarian, primary peritoneal, and fallopian tube cancer patients in India. J Clin Oncol 2019; 37 (Suppl. 15) e13073
• 28 Singh J, Thota N, Singh S, Padhi S, Mohan P, Deshwal S. et al. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: Prevalence of BRCA1/2 and non-BRCA mutations. Breast Cancer Res Treat 2018; 170: 189-96
• 29 Mannan AU, Singh J, Lakshmikeshava R, Thota N, Singh S, Sowmya TS. et al. Detection of high frequency of mutations in a breast and/or ovarian cancer cohort: Implications of embracing a multi-gene panel in molecular diagnosis in India. J Hum Genet 2016; 61: 515-22
• 30 Valarmathi MT, Sawhney M, Deo SS, Shukla NK, Das SN. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families. Hum Mutat 2004; 23: 205
• 31 Sharma S, Rajaram S, Sharma T, Goel N, Agarwal S, Banerjee BD. et al. Role of BRCA1 and BRCA2 gene mutations in epithelial ovarian cancer in Indian population: A pilot study. Int J Biochem Mol Biol 2014; 5: 1-0
• 32 Matthew WK, Becker M, Neff C, Abkevich V, Jones JT, Hou X, Wang Y. et al. Use of homologous recombination deficiency (HRD) score to enrich for niraparib sensitive high grade ovarian tumors. J Clin Oncol 2015; 33 (Suppl. 15) 5532
• 33 Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC. et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 2016; 22: 3764-73